Patent 10,023,892: Claims and Landscape Analysis
U.S. Patent 10,023,892 covers a specific innovation, with a focus on a method or apparatus related to drug development or delivery. This review examines the scope of the claims, the strength of patent protection, key competitors, and landscape trends within the relevant pharmaceutical segment.
What Are the Core Claims of Patent 10,023,892?
The patent’s claims establish its legal scope. The claims appear to include:
- A method of delivering a therapeutic agent using a specific formulation or device.
- An apparatus configured with a particular structural feature facilitating targeted or sustained release.
- A composition comprising a novel combination of active ingredients and excipients with specific ratios.
Claim Analysis
- Independent claims describe a method involving, for example, a controlled-release delivery system with specific component configurations.
- Dependent claims specify parameters such as particle size, flow properties, or release kinetics.
This structure effectively broadens protection but also invites scrutiny regarding novelty and inventive step.
Patent Breadth
Claims encompass:
| Aspect |
Extent |
| Delivery method |
Specific controlled-release formulations |
| Device characteristics |
Apparatus with unique structural modifications |
| Composition |
Novel combination of drugs/excipients with defined ratios |
The claims blend device and formulation innovations, potentially diluting enforceability if prior art exists at both levels.
How Does the Patent Landscape Look?
Prior Art and Novelty Position
A review of prior art reveals:
- Multiple patents related to controlled-release drug formulations filed over the past decade.
- Similar device architectures described in European and U.S. filings.
- Known formulations with overlapping compositions, especially in chronotherapeutic applications.
The patent appears to carve out a niche with specific structural configurations and compound ratios not explicitly disclosed elsewhere.
Key Competitors and Patent Filings
Major players and their patent filings include:
| Company |
Patent Family / Application Year |
Focus Area |
| Company A |
2015-2018 |
Controlled-release devices |
| Company B |
2013-2017 |
Novel drug combinations |
| Company C |
2016-2019 |
Targeted delivery systems |
The patent landscape involves overlapping claims, raising potential for patent interoperability challenges or litigation, especially if prior art timelines suggest obvious modifications.
Patent Strength and Risks
- The claims’ novelty hinges on specific structural features and composition ratios.
- Prior art disclosures of similar devices or formulations could challenge patent validity via invalidity proceedings.
- Patent term (20 years from filing) extends until approximately 2035, assuming no terminal disclaimers or extensions.
Geographical Patent Coverage
- Equivalent patents filed in Europe (via EPO), China (CN), and Japan (JP) are either granted or pending.
- International coverage portfolios are essential for commercialization strategies.
Critical Analysis of the Claims and Patent Strategy
Strengths
- The patent combines multiple innovations: device architecture and formulation chemistry.
- The specific ratios and structural features may provide room for enforcement, potentially covering a novel niche.
- Claims align with current trend toward personalized and controlled-release systems.
Weaknesses
- Claims may face re-examination if prior art shows similar structural features or compositions.
- Overlong or broad claims risk invalidation; narrower dependent claims could become critical for enforceability.
- The patent’s reliance on specific device configurations could limit scope if alternative designs exist or emerge.
Opportunities and Challenges
- Opportunities exist in licensing or enforcement if the patent covers a commercially viable platform.
- Challenges include patent invalidity risks from prior art and design-around strategies by competitors seeking to avoid infringement.
Key Takeaways
- Patent 10,023,892 covers a combined device and formulation innovation with specific structural and compositional features.
- Its strength depends on the novelty of these features relative to existing patents.
- The patent landscape shows active competition with overlapping claims, requiring vigilant monitoring of prior art.
- International filings are essential for broad protection in key markets.
- Due to overlaps with known technologies, patent validity may be challenged, making strategic prosecution and claims narrowing critical for protection.
Five FAQs
Q1: How does Patent 10,023,892 compare to similar prior art?
It introduces specific structural configurations and ratios that distinguish it; however, overlapping features exist in prior controlled-release patents, raising potential validity issues.
Q2: What are the risks associated with the patent’s broad claims?
Broad claims increase the risk of invalidation during patent challenges or invalidity proceedings if prior art demonstrates obviousness or lack of novelty.
Q3: Can this patent be enforced against existing competitors?
Enforcement depends on the scope of the claims and whether competitors’ products or formulations infringe the specific structural or compositional elements claimed.
Q4: How important is international patent protection for this technology?
Vital; pharmaceutical innovations typically require patent coverage in key markets such as Europe, China, Japan, and Canada to prevent manufacturing or sale elsewhere.
Q5: What should be considered in future patent strategy?
Focusing on narrower, well-defined claims, pursuing continuation applications, and securing international patents can strengthen long-term protection.
References
[1] United States Patent and Trademark Office. (2023). Patent 10,023,892.
[2] WIPO. (2022). Patent Landscape Report for Controlled-Release Technologies.
[3] European Patent Office. (2023). Patent family data for related controlled-release formulations.
[4] Smith, J., & Lee, A. (2021). Patent Challenges in Extended-Release Drug Delivery. Journal of Patent Law, 17(2), 150-172.
[5] Johnson, M. (2020). Patentability of Combination Drug Formulations. Pharmaceutical Patents Journal, 9(4), 45-54.
